(Q52103115)

English

Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: Studies in patients with chronic progressive multiple sclerosis

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: Studies in patients with chronic progressive multiple sclerosis (English)

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

author name string

F. Chiappelli

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1783458

22 November 2022

L. W. Myers

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1783458

22 November 2022

G. W. Ellison

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1783458

22 November 2022

D. Liao

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1783458

22 November 2022

J. L. Fahey

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1783458

22 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1783458

22 November 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

full work available at URL

https://api.elsevier.com/content/article/PII:019205619190064E?httpAccept=text/xml

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

https://api.elsevier.com/content/article/PII:019205619190064E?httpAccept=text/plain

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

International Journal of Immunopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

13

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

5

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

455-461

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus

1

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years

2

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

3

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone

4

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression.

6

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Correlation of clinical and immunologic states in multiple sclerosis

7

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters

8

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial

10

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis

11

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis

13

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Rheumatoid arthritis treated with chlorambucil: a five-year follow-up

16

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Autoimmunity in demyelinating diseases

18

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Immunotherapy of multiple sclerosis

19

1 reference

10.1016/0192-0561(91)90064-E

https://api.crossref.org/works/10.1016/0192-0561(91)90064-E

22 November 2022

Identifiers

10.1016/0192-0561(91)90064-E

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/1783458

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52103115&oldid=2113783868"